Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01853644 | Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer(TIVO) | completed | Phase 2 | 31 | Northwestern UniversityOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02853318 | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Oct 6, 2021 |
| clinicaltrials |
| NCT01252693 | International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer | completed | Phase 2 | 203 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 5, 2021 | clinicaltrials |
| NCT04453241 | Immunogenicity and Safety Study of NBP615 in Healthy Female | completed | Phase 1 / Phase 2 | 200 | SK Bioscience Co., Ltd.INDUSTRY | 1 | Oct 1, 2021 | clinicaltrials |
| NCT04050215 | 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer | completed | Phase 2 | 937 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT01105130 | L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors | completed | Phase 2 | 140 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT01535040 | Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking | completed | Phase 2 | 130 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT02499497 | A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer | completed | Phase 2 | 114 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT03062254 | Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy | completed | Phase 2 | 14 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Sep 21, 2021 | clinicaltrials |
| NCT02346578 | Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy. | completed | Phase 2 | 104 | Taro Iguchi, MD, PHDOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03192059 | Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer(PRIMMO) | completed | Phase 2 | 43 | University Hospital, GhentOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT03685695 | Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT02993705 | Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)(MITO 26) | completed | Phase 2 | 45 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT01804465 | Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer | completed | Phase 2 | 50 | University of California, San FranciscoOTHER | 1 | Aug 18, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT03394885 | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer(AdORN) | completed | Phase 1 / Phase 2 | 18 | Duke UniversityOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT02981368 | Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer(OSPREY) | completed | Phase 2 / Phase 3 | 385 | Progenics Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 9, 2021 | clinicaltrials |
| NCT00574678 | Analyzing the Composition of Tears to Identify Cancer(ACT) | completed | Phase 1 / Phase 2 | 150 | University of ArkansasOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT00214136 | Intensity Modulated Radiation Therapy (IMRT) Radiotherapy for Treating Prostate Pelvic Nodes | completed | Phase 2 | 30 | University of Wisconsin, MadisonOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT01505868 | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT01441635 | Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids | completed | Phase 2 | 271 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Jul 13, 2021 | clinicaltrials |
| NCT00806156 | Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer | completed | Phase 2 | 178 | Nektar TherapeuticsINDUSTRY | 3 | Jul 12, 2021 | clinicaltrials |
| NCT02463799 | Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC | completed | Phase 2 | 36 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT02867020 | Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels | completed | Phase 2 | 128 | Latin American Cooperative Oncology GroupOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT00667862 | Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer | completed | Phase 2 | 35 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 21, 2021 | clinicaltrials |
| NCT01706458 | Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer | completed | Phase 2 | 18 | University of Wisconsin, MadisonOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT01254513 | Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients(GERICO10) | completed | Phase 2 | 66 | UNICANCEROTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT02229734 | Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2(FASTR-2) | completed | Phase 2 | 60 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT02559115 | 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer | completed | Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT01503229 | Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 32 | University of WashingtonOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT01540071 | Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer | completed | Phase 2 | 38 | Io TherapeuticsINDUSTRY | 1 | May 14, 2021 | clinicaltrials |
| NCT01406769 | Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy | completed | Phase 2 | 120 | Gynecologic Oncology GroupNETWORK | 1 | May 7, 2021 | clinicaltrials |
| NCT00087165 | GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer | completed | Phase 2 | 22 | University Health Network, TorontoOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT01868386 | Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate(HypoFX) | completed | Phase 1 / Phase 2 | 32 | Timothy Showalter, MDOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02987829 | Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 72 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Apr 23, 2021 | clinicaltrials |
| NCT02046837 | An Exercise Trial and Economic Analysis in Men With Prostate Cancer(ADT Ex RCT) | completed | Phase 2 | 59 | University Health Network, TorontoOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT00350051 | ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer | completed | Phase 2 | 53 | BayerINDUSTRY | 2 | Apr 8, 2021 | clinicaltrials |
| NCT00737893 | Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy(ERECT) | completed | Phase 2 | 56 | Johns Hopkins UniversityOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT00945191 | Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer | completed | Phase 2 | 24 | Daiichi SankyoINDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT02552121 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 33 | Seagen Inc.INDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT03935204 | Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) | completed | Phase 2 | 627 | Xiamen UniversityOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT01317199 | Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer | completed | Phase 1 / Phase 2 | 143 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT02142608 | A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Bracco Diagnostics, IncINDUSTRY | 2 | Mar 29, 2021 | clinicaltrials |
| NCT01468532 | Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 25, 2021 | clinicaltrials |
| NCT01615120 | Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer | completed | Phase 2 | 77 | GTxINDUSTRY | 1 | Mar 24, 2021 | clinicaltrials |
| NCT01748500 | Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 21 | University Health Network, TorontoOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT03901118 | Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer | completed | Phase 2 | 47 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Mar 19, 2021 | clinicaltrials |
| NCT02249013 | Short-course HIPEC in Advanced Epithelial Ovarian Cancer | completed | Phase 2 | 15 | Professor Fernando Figueira Integral Medicine InstituteOTHER | 0 | Mar 18, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Oct 12, 2021source: clinicaltrials